Loading stock data…
VNRX
$2.43-0.19 (-7.25%)
Market ClosedLast close May 1
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
VolitionRx Limited in the Healthcare sector is trading at $2.43. The stock is currently near its 52-week low of $2.41, remaining 68.6% below its 200-day moving average. Technical signals show oversold RSI of 25 and bearish MACD signal, explaining why VNRX maintains its current current market pressure. The Whystock Score of 25/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Oversold momentum (RSI 25) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.43
Potential Upside
5%
Whystock Fair Value$2.55
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus3 analysts
Buy
Mean target$33.33+1271.7%
Range$20.00 – $60.00
Fundamentals
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$24.99M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.33
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
90.70%
Volume
Today's trading volume
226,524
Recent News
VolitionRX Ltd (VNRX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
VolitionRX Ltd (VNRX) reports a 133% year-on-year revenue growth and significant partnerships, despite ongoing financial challenges and unpredictable revenue streams.
VolitionRx Limited Q4 2025 Earnings Call Summary
Moby summary of VolitionRx Limited's Q4 2025 earnings call
VolitionRx announces automated Nu.Q Vet Cancer Test with Fujifilm Vet Systems
VolitionRx (VNRX) announces the completion of all validation and verification of the chemiluminescent immunoassay version of its Nu.Q Vet Cancer Test with Fujifilm Vet Systems Co. in Japan, allowing use of full automation rather than manual plates in central laboratories. Volition’s supply agreement enables Fujifilm Vet Systems to sell and perform the Nu.Q Vet Cancer Test throughout its network of central reference laboratories in Japan. Claim 70% Off TipRanks PremiumUnlock hedge fund-level data
VolitionRX Ltd (VNRX) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Revenue ...
VolitionRX Ltd (VNRX) reports a 32% revenue increase and strategic agreements, while navigating market unpredictability and capital challenges.
VolitionRX: Q3 Earnings Snapshot
HENDERSON, Nev. AP) — VolitionRX Ltd. (VNRX) on Thursday reported a loss of $5.4 million in its third quarter. The Henderson, Nevada-based company said it had a loss of 5 cents per share.